Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.70
+0.07 (1.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
Abeona Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Abeona Therapeutics stock have an average target of 18, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 215.79% from the current stock price of 5.70.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ABEO stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +163.16% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +163.16% | Oct 31, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $18 | Buy | Reiterates | $18 | +215.79% | Oct 29, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $18 | Buy | Reiterates | $18 | +215.79% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +163.16% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
102.00K
from 3.50M
Decreased by -97.09%
Revenue Next Year
19.19M
from 102.00K
Increased by 18,714.71%
EPS This Year
-1.73
from -2.53
EPS Next Year
-1.25
from -1.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 525,000 | 30.6M | 111.4M | |||
| Avg | 102,000 | 19.2M | 76.7M | |||
| Low | n/a | 13.7M | 55.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -85.0% | 29,855.9% | 480.5% | |||
| Avg | -97.1% | 18,714.7% | 299.7% | |||
| Low | - | 13,351.0% | 191.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.60 | -1.06 | -0.08 | |||
| Avg | -1.73 | -1.25 | -0.50 | |||
| Low | -1.76 | -1.48 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.